Agendia Announces Colorectal Cancer Research Collaboration With Leading Cancer Centers - MD Anderson Cancer Center and Netherlands Cancer Institute

By Agendia, PRNE
Wednesday, June 8, 2011

AMSTERDAM, The Netherlands, and IRVINE, California, June 9, 2011 -

Agendia, a commercial-stage molecular cancer diagnostics company,
announces today that it has entered into a research collaboration with The
University of Texas MD Anderson Cancer Center, one of the world's leading
cancer centers and whose research program is considered one of the most
productive in the world aimed solely at cancer, and the Netherlands Cancer
Institute (NKI) with the aim of improving diagnosis and treatment options of
colorectal cancer patients. The work is based on an approach toward
integrating several genomic and proteomic technologies in order to study
patterns of gene and protein expression in cancerous tumors that may, when
combined, provide greater insight into the unique biology of individual
patients' tumors and why patients often have different prognosis and varied
responses to the same treatment.

Colorectal cancer is a leading cause of cancer-related death worldwide,
with more than 1.2 million new cases each year. Though early detection and
better treatment options have resulted in improved prognoses for many
patients, more than half of colorectal cancer patients still die from the
disease. While past researchers have often looked at just one aspect of the
cancer's progression, the new integrated approach utilized by MD Anderson,
NKI and Agendia will analyze colorectal cancer samples on multiple levels.
Specifically the collaboration will study the active genome (gene
expression), mutation status and protein activation measured in the same
sample and combine results with pathological and clinical data.

"In MD Anderson and NKI we have found not only experts in the fields of
functional genomics, proteomics, and clinical oncology, but also partners who
share our commitment to putting the most effective tools in the hands of
physicians and their patients to simplify difficult cancer decisions," said
Bernhard Sixt, Chief Executive Officer of Agendia.

In addition to a better understanding of the individual biology, this
collaboration will allow an independent validation of ColoPrint(R), Agendia's
colon cancer recurrence test. Agendia is currently developing ColoPrint(R),
which works by identifying Stage II colon cancer patients who are either at
low risk or at high risk of experiencing a disease recurrence. As
demonstrated in previous validation studies for Agendia's currently marketed
products, ColoPrint(R), when combined with clinical parameters, has the
potential to provide clinicians with a more reliable means to assist them in
treatment decision-making for patients with Stage II colon cancer.

"The unique structure of this consortium makes possible the rapid
translation of results from research and discovery to clinical setting that
benefits patients sooner," said Scott Kopetz, MD, PhD, principal investigator
of this research consortium and Assistant Professor in the Department of
Gastrointestinal Medical Oncology at MD Anderson.

About Agendia

Agendia is an innovative molecular diagnostic company, striving to
develop more effective, individualized treatments within reach of patients.
Building on a genomics platform for tumor gene expression profiling, the
company's tests help physicians more accurately select a course of cancer
treatment for their patients. Agendia markets four products, with several new
genomic tests under development. In addition, Agendia collaborates with
pharmaceutical companies to develop companion diagnostic tests in the area of
oncology. Agendia is based in Amsterdam, the Netherlands and in Irvine,
. For more information, please visit

    For further information, please contact:


    Dr. Bernhard Sixt, President & CEO
    International media and investor enquiries


    Mary-Jane Elliott / Emma Thompson
    Tel: +44(0)20-7920-2345, E-mail:

    Dutch media enquiries

    Huijskens Communications
    Ian Bickerton
    Tel: +31(0)20-685-5955, E-mail:

    US Media enquiries

    Ricochet Public Relations
    Valerie Carter
    Tel: +1-202-316-0143, E-mail:


will not be displayed